Biogen’s controversial Alzheimer’s drug generates $2 million sales in first few weeks after …

biogens controversial alzheimers drug generates 2 million sales in first few weeks after approval

Sumary of Biogen’s controversial Alzheimer’s drug generates $2 million sales in first few weeks after approval:

  • Aduhelm by BiogenSource: BiogenBiogen’s Alzheimer’s drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said Thursday in releasing its second-quarter earnings along with an open letter about the controversial drug.
  • Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates compiled by Refinitiv:Adjusted EPS: $5.68 vs $4.54 expectedRevenue: $2.78 billion vs $2.61 billion expectedShares of the company rose slightly in early trading.
  • Biogen’s top research chief, Dr. Al Sandrock, defended the drug in an open letter released alongside the company’s earnings Thursday, saying its approval has been subject to “extensive misinformation and misunderstanding.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close